---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-071470"
form_type: "8-K"
ticker: null
cik: "0001634379"
company_name: "Metacrine, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:05:07.547851+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Metacrine sells FXR program to Organovo for $4M cash

## Summary
- Sold FXR program technology, including trial data and IP, to Organovo for $2.0M upfront and up to $2.0M additional.
- Transaction closed on March 10, 2023; additional $2M due within 5 business days of delivery of certain assets.
- Parties entered into a Patent Assignment for FXR-related intellectual property rights.

## SEC filing metadata
- accession: 0001193125-23-071470
- form_type: 8-K
- cik: 0001634379
- company_name: Metacrine, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/d474257d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-071470
- JSON: https://secwatch.observer/filing/0001193125-23-071470.json
- Plain text: https://secwatch.observer/filing/0001193125-23-071470.txt

## Key facts
- M&A Transactions
  Metacrine, Inc. completed a disposition involving Organovo, Inc. for $2.0 million in cash (closed 2023-03-10).
  - Action: disposition
  - Counterparty: Organovo, Inc.
  - Consideration: $2.0 million in cash
  - Closing: 2023-03-10
  source text: property rights relating to its FXR program. As consideration for the Assets, under the terms of the Asset Agreement, Purchaser paid the Company an upfront payment of $2.0 million in cash and agreed to make an additional payment of $2.0 million in cash within five business days of the Company’s delivery of certain assets sold pursuant to the Asset
  evidence_url: https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm
- Material Agreements
  Metacrine, Inc. entered into Asset Agreement with Organovo, Inc. valued at $2.0 million (effective 2023-03-10).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Organovo, Inc.
  - Value: $2.0 million
  - Effective: 2023-03-10
  source text: On March 10, 2023, Metacrine, Inc. (the “Company”) entered into and closed the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Agreement”) with Organovo, Inc. (“Purchaser”), pursuant to which the Company sold to Purchaser the right, title and interest in and to its farnesoid X receptor (“FXR”) program technology including all inventory, trial data and research records relating to its FXR program (collectively, the “Assets”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1634379/000119312523071470/0001193125-23-071470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.